Download PDF
Thromb Haemost 2008; 100(04): 517-518
DOI: 10.1160/TH08-08-0545
Editorial Focus
Schattauer GmbH

Dyspnea and antiplatelet drugs: Little cause for concern with clopidogrel

Rickard E. Malmström
1   Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
,
Paul Hjemdahl
1   Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 25 August 2008

Accepted 25 August 2008

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
    CrossrefPubMedGoogle Scholar
  • 2 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
    CrossrefPubMedGoogle Scholar
  • 3 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
    CrossrefPubMedGoogle Scholar
  • 4 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
    CrossrefPubMedGoogle Scholar
  • 5 Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 61: 529-533.
    CrossrefPubMedGoogle Scholar
  • 6 Husted S, van Giezen JJJ. Dyspnoea and antiplatelet agents: revisited. Int J Clin Pract 2007; 61: 1590-1591.
    CrossrefPubMedGoogle Scholar
  • 7 Serebruany V, Pokov I, Kuliczkowski W. et al. Incidence and causes of new-onset dyspnea in 3,179 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb Haemost 2008; 100: 314-318.
    Article in Thieme ConnectPubMedGoogle Scholar